Conflicting roles for protein kinase C (PKC) isozymes in cardiac disease have been reported. Here, ␦PKC-selective activator and inhibitor peptides were designed rationally, based on molecular modeling and structural homology analyses. Together with previously identified activator and inhibitor peptides of PKC, ␦PKC peptides were used to identify cardiac functions of these isozymes. In isolated cardiomyocytes, perfused hearts, and transgenic mice, ␦PKC and PKC had opposing actions on protection from ischemiainduced damage. Specifically, activation of PKC caused cardioprotection whereas activation of ␦PKC increased damage induced by ischemia in vitro and in vivo. In contrast, ␦PKC and PKC caused identical nonpathological cardiac hypertrophy; activation of either isozyme caused nonpathological hypertrophy of the heart. These results demonstrate that two related PKC isozymes have both parallel and opposing effects in the heart, indicating the danger in the use of therapeutics with nonselective isozyme inhibitors and activators. Moreover, reduction in cardiac damage caused by ischemia by perfusion of selective regulator peptides of PKC through the coronary arteries constitutes a major step toward developing a therapeutic agent for acute cardiac ischemia.
T
here are conflicting reports on the role of protein kinase C (PKC) in mediating myocardial protection from ischemia (1) . Moreover, changes in the expression of some PKC isozymes in cardiac hypertrophy and heart failure (2-4) could reflect either their active role or a consequence of these diseases. Current approaches include the use of isozyme nonselective tools and overexpression of individual PKC isozymes, which prevent a meaningful interpretation of the data.
Each of the six PKC isozymes in cardiac myocytes translocates to different subcellular sites upon activation (5-7). We proposed a mechanism for isozyme-specific translocation involving binding of activated PKC to isozyme-specific anchoring proteins termed RACKs [receptors for activated C kinase (7)]. Binding of a specific PKC isozyme to its RACK occurs after phospholipid-induced allosteric conformational changes that activate the enzyme and expose its RACK-binding domain. This leads to PKC translocation and binding to isozyme-specific RACKs at different subcellular sites, which is thought to determine the function of each isozyme (5, 6) . Based on this hypothesis, we developed several peptide translocation inhibitors and activators, which when introduced into cells, cause selective regulation of translocation and function of the corresponding PKC isozyme (8) .
Translocation inhibitor peptides correspond to specific RACK-binding sites in the C2͞V1 domain (9) (10) (11) (12) of each isozyme and act as isozyme-selective competitors of PKC-RACK binding and function (10, 12) . Peptide activators, on the other hand, are derived from a pseudoRACK (RACK) sequence in each PKC isozyme that is similar to a sequence in its corresponding RACK (8, 10, 13) . These RACK or RACK-like PKC sequences are thought to engage in intramolecular interactions with the RACK-binding site in PKC, thus stabilizing PKC in its inactive ''closed'' conformation (8, 10, 13) . Therefore, interference with this intramolecular interaction and destabilization of the inactive enzyme should enhance PKC translocation and binding to its RACK, thus stabilizing the activated state of that PKC isozyme. Using this rationale, we identified isozymeselective activator peptides for ␤PKC and PKC (10, 13) . Relevant to this study, these activator peptides were used to show that PKC confers cardiac protection from transient ischemic insult (13) and normal postnatal cardiac development (14) . In this study, we used a rational approach to identify ␦PKC inhibitor and activator peptides and used them to determine the role of ␦PKC in cardiac functions. V1 Structure Prediction. We used the sequence alignment of the C2͞V1 (17) and then modeled V1 according to ␦V1 (Protein Data Bank accession no. 1BDY), the C2 domain in phospholipase ␦1 (Protein Data Bank accession no. 2ISD), and 115-132 of the carboxypeptidase (Protein Data Bank accession no. 1LBU), which has sequence homology to a long gap in the alignment corresponding to residues 16-30 of V1.
Materials and Methods

Isolation of Adult Rat Cardiac Myocytes and Simulated Ischemia.
Cardiac myocytes from 12-week-old male Wistar rats were isolated as described (13) , treated with peptide conjugates in the presence or absence of phorbol 12-myristate 13-acetate (PMA), and subjected to Western blot analysis (13, 18) or simulated ischemia (13, 18) . To simulate ischemia, we kept cardiac myocyte pellets for either 90 or 180 min in sealed test tubes in a small volume of buffer, saturated in N 2 and devoid of oxygen (Ͻ0.5%), glucose, and nutrients (19) . We assessed damage to cardiac myocytes by trypan blue dye exclusion assay (19, 20) . The staining correlates with increased myocyte rounding, propidium iodide staining, membrane blebbing, and leak of cytosolic enzymes into the cell medium (18) .
Simulated Ischemia in Intact Rat Hearts. We simulated ischemia for 45 min in isolated hearts from 12-to 20-week-old rats by using Langendorff apparatus (18) and determined damage by creatine kinase (CK; used also as a diagnostic marker for cardiac damage in patients) activity (Sigma) in perfusate collected during 30 min Abbreviations: PKC, protein kinase C; RACK, receptor for activated C kinase E; RACK, pseudoRACK; PMA, phorbol 12-myristate 13-acetate; CK, creatine kinase. ¶ To whom reprint requests should be addressed. E-mail: mochly@stanford.edu.
The publication costs of this article were defrayed in part by page charge payment. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. §1734 solely to indicate this fact. of reperfusion. Peptide delivery conjugates were added to perfusion buffer 20 min before simulated ischemia. Assays were always performed within 24 h of the experiment. There was no change in CK activity over this period.
Hemodynamic Measurements of Transgenic Mice. Hemodynamic parameters were monitored in 12-week-old transgenic mice and their littermates. Mice were anesthetized with avertin i.p., and hearts were rapidly removed and cannulated via the aorta for retrograde perfusion with Kreb-Henseleit buffer on a Langendorff apparatus. Left ventricular pressure and real-time derivative (dP͞dt) was monitored via a catheter placed in the ventricular apex. These parameters were measured for 20 min until equilibration. Simulated ischemia was induced by interruption of buffer perfusion for 35 min. Hemodynamic measurements were taken every 20 sec throughout 30-min reperfusion (13) .
Dry Heart Weights and Fractional Shortening. Left ventricular fractional shortening was measured in transgenic mice and their littermates as described (13, 21) . Hearts from 12-week-old transgenic and nontransgenic animals were desiccated, and dry weight was determined to demonstrate hypertrophy in transgenic mice. Dot Blot Analysis of mRNA. We determined cardiac gene expression from transgenic mice and their littermates by RNA dot Northern blot analysis of total ventricular RNA (3 g͞dot) by using 32 P-labeled oligonucleotide probes as described (21) .
Simulated Ischemia in Vivo.
Using open chest coronary occlusion and a nontraumatic balloon inflation, we induced ischemia at 37°C (22, 23) for 30 min. To identify the infarcted myocardium, 24 h after occlusion, we perfused the hearts on Langendorff apparatus with a 1% solution of 2,3,5-triphenyltetrazolium chloride (22, 23) . Region at risk was determined by tying the coronary artery at the site of the previous occlusion and perfusing hearts with a 5% solution of phthalo blue dye (Heucotech, Fairless Hill, PA). Using computerized video planimetry of transverse slices, we calculated infarct size as a percentage of the region at risk (22, 23) .
Hemodynamic Measurements, Dry Heart Weights, and Dot Blot Analysis of mRNA. We measured left ventricular fractional shortening, changes in cardiac weight, and gene expression as described (13, 21) .
Results
Rational Design of ␦PKC Selective Inhibitor and Activator Peptides. In the absence of any information about the ␦RACK sequence, we used a rational design to identify ␦PKC-selective activator and inhibitor peptides. We had previously observed that the V1 domain of ␦PKC contains the RACK-binding site (12) . We then considered that of the three other novel PKC isozymes (, , and ), ␦PKC is most similar to PKC (52% amino acid identity in the first variable or V1 domain) (24, 25) . Because each PKC isozyme should interact with a different RACK, we predicted that the sequences that are the least similar between ␦PKC and PKC were likely to mediate RACK binding. Based on this assumption, we identified three regions in the V1 domain of ␦PKC with only Ϸ10% identity to PKC (colored bars in Fig. 1A) .
To determine which of the peptides corresponding to these sequences was most likely to be a ␦PKC inhibitor or activator, we compared the tertiary structure of ␦V1 (previously solved in ref. 26) to the structure of V1 that we modeled (Fig. 1B; (G.C., D.M.-R., and L.B., unpublished work). Both the ␦V1 domain and the modeled V1 domain are composed of two ␤-sheets (Fig. 1C and schematically presented in Fig. 1B) . We selected the first (␦V1-1) and the third (␦RACK) unique ␦V1 sequences as potential ␦PKC-selective inhibitor and activator peptides, because their positions in the structure overlap that of V1-2, the PKC-selective inhibitor peptide (12) , and RACK (13), the PKC-selective activator peptide, respectively (red and green in Fig. 1 B and C) .
To determine whether the ␦PKC peptides had the anticipated activities, we delivered the peptides conjugated to Antennapedia carrier peptide into isolated adult rat cardiac myocytes (13) . As predicted, ␦V1-1 inhibited PMA-induced ␦PKC translocation, but not the translocation of PKC (Fig. 1D) or ␣PKC (not shown). ␦RACK had an opposite effect to that of ␦V1-1; i.e., it selectively induced ␦PKC translocation in cardiac myocytes, without affecting the translocation of ␣PKC (Fig. 1E) or PKC (not shown). Furthermore, basal partitioning of ␦PKC in the particulate fraction was inhibited by ␦V1-1, and ␦RACK reversed this ␦V1-1 effect (Fig.  1F ). Similar to our data on the PKC activator and inhibitor peptides (13, 27) , scrambled peptides cross-linked to Antennapedia, or Antennapedia peptide alone had no effect on ␦PKC translocation (not shown). In addition, ␦V1-1 and ␦RACK also caused the same selective effect on hormone-induced translocation of ␦PKC as determined by immunofluorescence and Western blot analysis (not shown). Furthermore, peptides applied to ␦PKC or PKC in vitro had no effect on enzymatic activity (not shown), demonstrating their specific effects on translocation. Therefore, ␦V1-1 is a selective translocation inhibitor and ␦RACK is a selective translocation activator of ␦PKC.
Role of ␦PKC in Simulated Cardiac Ischemia in Isolated Adult Cardiac
Myocytes. Using the PKC translocation activator, RACK, we recently observed that activation of PKC is necessary and sufficient to confer protection from ischemic injury in isolated cardiomyocytes and transgenic mice (13) . Because ␦PKC is also translocated during ischemia (13, 27) , we used the ␦PKC activator peptide, ␦RACK, and the ␦PKC inhibitor peptide, ␦V1-1, to determine the role of ␦PKC in protection from ischemia. We added ␦V1-1 conjugated to Antennapedia to cardiomyocytes 10 min before 180-min simulated ischemia and found a concentration-dependent protection of cardiac myocytes from ischemic damage (Fig. 2A) . Moreover, ␦V1-1 protection was reversed by coincubation with the ␦PKC activator, Fig. 2 . Ischemic damage is due, in part, to ␦PKC activation. (A) Isolated rat cardiac myocytes from adult male rats (13, 18) were pretreated with the ␦PKC-selective inhibitor peptide, ␦V1-1, and͞or activator peptide, ␦RACK (green), before simulated ischemia. Control is ␤PKC-selective activator (10) . Statistical analysis compares all data to those obtained from cells treated with no peptide (blue). (B) As in A, but ischemic period was shortened to illustrate an additive effect between ␦RACK and ischemia in inducing damage. Statistical analysis compares data from cells treated with no peptide (blue; * ) and with ␦RACK in the presence of ␦V1-1 (red plus green; ** ) to cells treated with ␦RACK alone (green). (C) Whole hearts from adult male rats were perfused with the ␦PKC-selective inhibitor peptide ␦V1-1 or activator peptide ␦RACK before global ischemia followed by reperfusion using the Langendorff preparation (13, 18) . Shown is average levels over time. (D) Total CK released over the 30-min reperfusion (13, 18) are shown and include the effect of infusion of the PKC-selective activator, RACK (magenta). Controls (second blue bar) include peptides coupled to Tat-carrier peptide with a scrambled sequence or a nonrelevant sequence and Tat-carrier peptide alone. All measurements were carried out in triplicate, using 3-4 animals per condition.
␦RACK, but not with ␤PKC-selective translocation activators (28) or other control peptides (Fig. 2 A and not shown) .
In addition to the opposing protective effect induced by ␦V1-1, ␦RACK caused a slight increase in myocyte damage after an ischemic insult (Fig. 2 A) . When we reduced the time of ischemia from 180 to 90 min, the ␦RACK-induced increase in cell damage became significant and was partially reversed by cotreatment with the ␦PKC inhibitor, ␦V1-1 (Fig. 2B) . Therefore, cell damage induced by simulated ischemia is caused, at least in part, by activation of ␦PKC.
Role of ␦PKC and PKC in Simulated Ischemia in Intact Heart. We recently found that conjugation of PKC inhibitor or activator peptides to a Tat-derived peptide [Tat 47-57 (16)] enables their delivery through the coronary arteries into intact heart (34). Therefore, to determine the role of ␦PKC and PKC on cardiac damage caused by 45 min of no-flow myocardial ischemia, we perfused Tat-conjugated peptide regulators of these isozymes into isolated rat hearts. As predicted from our previous cellular and transgenic studies (13) , acute activation of PKC by infusion of RACK through the coronary arteries protected the heart from ischemia by more than 60% (Fig. 2 C and D) . In contrast, activation of ␦PKC with ␦RACK increased cardiac damage by Ϸ30% (Fig. 2 C and D) . Moreover, acute inhibition of ␦PKC by infusion of ␦V1-1 protected isolated hearts from ischemic damage as shown by decreased release of CK ( Fig. 2 C and D) . Scrambled peptides cross-linked to Tat-derived peptide, peptides not linked to Tat-derived carrier peptide, or Tat-derived peptide alone had no effect on the response of the hearts to ischemic insult (Fig. 2D) . Together, these data indicate that in the intact heart as well as in cardiac myocytes, these two closely related PKC isozymes have opposing effects; inhibition of ␦PKC or activation of PKC both conferred at least 50% protection against ischemic damage (Fig. 2D) .
Our data demonstrating that ␦PKC activity increases damage by cardiac ischemia may be in contrast to the study of Kihara and collaborators (29) , using a compound that alters the subcellular location of ␦PKC (JTV). They suggested that ␦PKC protects isolated rat cardiomyocytes from ischemic damage. However, the drug, which was initially designed to affect annexin, a phospholipid-binding protein, may in fact sequester ␦PKC and thus inhibit its normal activity.
Role of ␦PKC and PKC in Simulated Ischemia in Transgenic Mice. To determine the consequences of sustained activation of ␦PKC by expression of ␦RACK, we created transgenic mice in which the ␣-myosin heavy chain promoter drove expression of ␦RACK, as described for RACK (13) . Multiple independent lines of ␦RACK mice exhibited identical phenotypes, including increased association of ␦PKC with the subcellular particulate as a percent of the region of risk in mice with sustained ␦PKC activation (␦RACK mice; green bar) and nontransgenic littermates (white bar) was determined in vivo after coronary occlusion followed by 24 h of reperfusion as described (mean Ϯ SEM) (22, 23) . The area at risk was not significantly different between the nontransgenic and ␦RACK mice (36 Ϯ 3% and 41 Ϯ 5% of left ventricle for nontransgenic and ␦RACK mice, respectively). Data are from eight 30-to 34-week-old transgenic females and five nontransgenic female littermates. So far only three males were available for analysis and therefore they are not included in the analysis; in all of the other studies, equal numbers of male and female transgenic and nontransgenic mice were used. (E) Example of infarcts in a ␦RACK transgenic mouse (Right) and a littermate (Left) subjected to coronary occlusion and 24 h of reperfusion in vivo. The portion of the left ventricle supplied by the occluded coronary artery (region of risk) was identified by the absence of Phthalo blue dye, which was perfused only through the nonoccluded vascular bed (22, 23) . The infarcted area was identified by perfusion with 2,3,5-triphenyltetrazolium chloride, which stains viable tissue bright red, whereas infarcted tissue is light yellow (22, 23) . fraction (Fig. 3A Upper) . We found no changes in overall ␦PKC levels or in the levels and subcellular association of other PKC isozymes (Fig. 3A and not shown.) For comparison, parallel experiments were carried out by using RACK transgenic mouse hearts (Fig. 3A Lower) . We next determined functional recovery and cardiomyocyte damage in ␦RACK and RACK mouse hearts after transient (35 min) no-flow global ischemia. Consistent with the results obtained when peptides were acutely introduced into isolated cardiomyocytes ( Fig. 2 A and B) or perfused rat hearts ( Fig. 2 C and D) , the ␦RACK mouse hearts showed significantly impaired recovery of systolic (contraction, ϩdP͞dt) and diastolic (relaxation, ϪdP͞dt) functions from ischemia ( Fig. 3B ; P Ͻ 0.05 and Table 1 ). In contrast, we previously found that RACK mouse hearts had significantly improved recovery of cardiac functions after ischemia (13) . Furthermore, a significant decrease in cellular damage (CK release) during reperfusion was observed in RACK-expressing mice (Fig.  3C, magenta) , but not in ␦RACK-expressing mice (Fig. 3C , green bar).
Role of ␦PKC in Simulated Ischemia in Vivo. Next, we used a physiologically relevant mouse model of acute ischemic injury induced by a 30-min in vivo coronary occlusion (22, 23) and measured infarct size 24 h after reperfusion. Although the area at risk for infarction was similar in the two groups, ␦RACK mice exhibited over a 2-fold increase in infarct size as compared with nontransgenic littermates (Fig. 3D) . The marked in vivo increase in myocyte death in the transgenic mice with sustained ␦PKC activation (␦RACK) is illustrated in Fig. 3E , where a much larger light yellow area (infarcted area) is seen in the ␦RACK heart than in the nontransgenic heart. Therefore, activation of ␦PKC exacerbates damage during ischemia in three different models: isolated myocytes, intact hearts ex vivo, and intact hearts in vivo, which is in contrast to the protective role of PKC in ischemia (here and ref. 13 ).
Role of ␦PKC and PKC in Cardiac Hypertrophy. We previously observed that older transgenic mouse hearts with sustained PKC activation (RACK mice) developed increased myocardial mass (hypertrophy) with normal contractile function, whereas mice with sustained inhibition of PKC activation developed lethal dilated cardiomyopathy (21) . Given the opposing effects of ␦PKC and PKC on cardiac injury in response to simulated ischemia shown here, we anticipated that transgenic mice with sustained activation of ␦PKC (␦RACK mice) would exhibit an effect on myocardial hypertrophy opposite to that of RACK. Unexpectedly, the ␦RACK mice also developed an increase in cardiac mass similar to age-matched RACK mice (Fig. 4A) . Note, however, that these mice had normal basal and ␤-adrenergic-stimulated contractile function (Fig. 4B and Table  2 ; ref. 21 ) and a normal histological appearance (ref. 21 for PKC, and data not shown for ␦PKC). Furthermore, both transgenic lines of mice developed identical perturbations of gene expression; a selective increase in expression of the ␤-myosin heavy chain gene, a known marker for cardiac hypertrophy in mice (Fig. 4C) (30, 31) . Therefore, the molecular and functional characteristics of cardiac hypertrophy in the ␦RACK and the RACK mice appear identical, indicating a parallel role for ␦PKC and PKC in regulation of cardiac hypertrophy. Echocardiogram measurements were taken as described (13, 21) . In vivo catheterization measurements shown for baseline and ␤-adrenergic-stimulated contractile function (dobutamine, 1 ng͞g per min for 3 min; dose was continuously doubled up to 32 ng͞g per min). Data are mean Ϯ SEM of nine ␦RACK and nine nontransgenic mice of 12 weeks of age. * , P ϭ not significant for all measurements. Positive developed pressure over time (ϩdP͞dt) and negative developed pressure over time (ϪdP͞dt) were recorded throughout reperfusion (13) . Data were taken 7 min after reperfusion and are mean Ϯ SEM of 12 ␦RACK and 11 nontransgenic mice of 12 weeks of age. * , P Ͻ 0.05. Fig. 4 . ␦RACK transgenic mice exhibit hypertrophy similar to RACK mice. (A) Dry heart weights of nontransgenic and ␦RACK-expressing transgenic mice were measured as in ref. 13 , demonstrating hypertrophy in hearts of ␦RACK and RACK mice. Data are mean Ϯ SEM from 10 ␦RACK mice (green bar), five nontransgenic mice (white bar), and three RACK mice (magenta bar). (B) Left ventricular fractional shortening was measured in the nontransgenic and transgenic mice as described (13, 21) . Data are mean Ϯ SEM obtained from nine ␦RACK mice (green bar), 10 nontransgenic mice (white bar), and four RACK mice (magenta bar). (C) Dot blot analysis of mRNA from hearts of transgenic and nontransgenic mice showing increased expression of ␤MHC, a marker for hypertrophy (33) . GADPH, glyceraldehyde-3-phosphate dehydrogenase; ␣MHC, ␣-myosin heavy chain; ␤MHC, ␤-myosin heavy chain; ANF, atrial natriuritic factor; SERCA, sarcoplasmic reticular ATPase; PLB, phospholamban; ␣SK actin, ␣ skeletal actin.
Discussion
We have used selective inhibitor and activator peptides of ␦PKC and PKC translocation to show opposing roles in response to ischemia and similar roles in cardiac hypertrophy for these two isozymes. We presented data demonstrating the role of these isozymes in cardiac protection from ischemia by using two species (rat and mouse), three model systems for simulated ischemia (isolated myocytes, intact heart, and in vivo), three methods of peptide delivery (transgene and acute peptide delivery using Antennapedia-or Tat-carrier peptides), and at least four methods of damage assessment (CK release, dye exclusion, functional recovery of contraction, and infarct size). Therefore, multiple independent methods used to assess the role of ␦PKC and PKC yielded the same conclusion: inhibiting ␦PKC or activating PKC reduce damage from simulated ischemia. Similarly, using multiple methods we found that activation and translocation of ␦PKC and PKC isozymes in transgenic mice cause cardiac hypertrophy.
These data raise four important points. First, it is possible to identify highly efficacious activator and inhibitor peptides of ␦PKC translocation, using a structure-based rational design.
[These peptides were active at intracellular concentrations of Ϸ25-50 nM, about 5-10% of the applied concentration (8) .] To our knowledge, there are no examples of rationally designed activators of signaling enzymes that act intracellularly except for our own. The development of these selective regulators of ␦PKC relied not only on the assumption that PKC-RACK interactions could be regulated as a means to selectively modify ␦PKC activity, but was achieved without any knowledge of the ␦PKC binding protein, ␦RACK. This method provides an alternative to mutational mapping of protein-protein interactions or random peptide library searches requiring the presence of both proteins and should be generally applicable to research on other proteinprotein interactions.
Second, our findings that PKC isozymes can exert an opposing effect on one function and the same effect on another function in a single cell can explain contradictory findings when isozyme nonselective drugs are used. We suggest that previous conflicting reports on the role of PKC in ischemic preconditioning (1), for example, may reflect such use of drugs that do not distinguish between ␦PKC and PKC.
Third, our observation that ␦PKC and PKC have opposing effects on ischemic injury was particularly unexpected, because in rats and mice both isozymes are activated by simulated ischemia as well as by stimuli that lead to cardioprotection from ischemia (18, 27) . These opposing forces (''yin yang'') illustrate the need for selective therapeutic agents to treat ischemic heart disease.
Finally, we show that these biologically active peptides can be effectively delivered into organs via the blood vessels by using Tat-conjugated peptides. Moreover, this mode of peptide delivery also should be useful for the study of other diseases in intact animals. Because delivery is immediate, it is superior to gene delivery, as adaptations to the changes induced by a signal transduction modulator are less likely to occur. Because we found a greater than 50% reduction in cardiac damage caused by ischemia by coronary perfusion of ␦PKC translocation inhibitor peptide or PKC activator peptide, we believe that these peptides may be useful therapeutic agents for acute cardiac ischemia.
